Prolonged usage of BENZODIAZEPINES and Z-DRUGS for the medium to long-term is ill advised due to inducing DOWN-REGULATION of the GABA RECEPTORS though GABA RECEPTOR AGONISM mechanism of action, causing TOLERANCE as well as WITHDRAWAL and REBOUND symptoms upon their cessation, as well as ADDICTION.
However, recent research now indicates that ANY usage of BENZODIAZEPINES and Z-DRUGS, even SHORT-TERM or INFREQUENT USAGE is ill advised, due to usage being associated with INCREASED MORTALITY (REDUCED LIFESPAN).
See the following study, published on 27th FEBRUARY 2012:
BMJ Open. 2012 Feb 27. doi:10.1136/bmjopen-2012-000850
Hypnotics' [Benzodiazepines’ and Z-Drugs’] association with mortality or cancer: a matched cohort study
Kripke DF, Langer RD, Kline LE
Source
1Scripps Clinic Viterbi Family Sleep Center, La Jolla, California, USA
2Jackson Hole Center for Preventive Medicine, Jackson, Wyoming, USA
EXTRACT FROM FULL TEXT
Abstract
Objectives
An estimated 6%–10% of US adults took a hypnotic [Benzodiazepine or Z-Drug] drug for poor sleep in 2010. This study extends previous reports associating hypnotics [Benzodiazepines and Z-Drugs] with excess mortality.
Setting
A large integrated health system in the USA.
Design
Longitudinal electronic medical records were extracted for a one-to-two matched cohort survival analysis.
Subjects
Subjects (mean age 54 years) were 10 529 patients who received hypnotic [Benzodiazepine or Z-Drug] prescriptions and 23 676 matched controls with no hypnotic [Benzodiazepine or Z-Drug] prescriptions, followed for an average of 2.5 years between January 2002 and January 2007.
Main outcome measures
Data were adjusted for age, gender, smoking, body mass index, ethnicity, marital status, alcohol use and prior cancer. Hazard ratios (HRs) for death were computed from Cox proportional hazards models controlled for risk factors and using up to 116 strata, which exactly matched cases and controls by 12 classes of comorbidity.
Results
As predicted, patients prescribed any hypnotic [Benzodiazepine or Z-Drug] had substantially elevated hazards of dying compared to those prescribed no hypnotics. For groups prescribed 0.4–18, 18–132 and >132 doses/year, HRs (95% CIs) were 3.60 (2.92 to 4.44), 4.43 (3.67 to 5.36) and 5.32 (4.50 to 6.30), respectively, demonstrating a dose–response association. HRs were elevated in separate analyses for several common hypnotics, including zolpidem, temazepam, eszopiclone, zaleplon, other benzodiazepines, barbiturates and sedative antihistamines. Hypnotic [Benzodiazepine or Z-Drug] use in the upper third was associated with a significant elevation of incident cancer; HR=1.35 (95% CI 1.18 to 1.55). Results were robust within groups suffering each comorbidity, indicating that the death and cancer hazards associated with hypnotic [Benzodiazepine or Z-Drug] drugs were not attributable to pre-existing disease.
Conclusions
Receiving hypnotic [Benzodiazepine or Z-Drug] prescriptions was associated with greater than threefold increased hazards of death even when prescribed <18 pills/year. This association held in separate analyses for several commonly used hypnotics and for newer shorter-acting drugs. Control of selective prescription of hypnotics for patients in poor health did not explain the observed excess mortality.
Article summary
Article focus
Estimate the mortality risks associated with specific currently popular hypnotics in a matched cohort design, using proportional hazards regression models.
Estimate the cancer risks associated with specific currently popular hypnotics.
Explore what risk associated with hypnotics can be attributed to confounders and comorbidity.
Key messages
Patients receiving prescriptions for zolpidem, temazepam and other hypnotics [Benzodiazepines or Z-Drugs] suffered over four times the mortality as the matched hypnotic-free control patients.
Even patients prescribed fewer than 18 hypnotic [Benzodiazepine or Z-Drug] doses per year experienced increased mortality, with greater mortality associated with greater dosage prescribed.
Among patients prescribed hypnotics [Benzodiazepines or Z-Drugs], cancer incidence was increased for several specific types of cancer, with an overall cancer increase of 35% among those prescribed high doses.
Introduction
Hypnotic [Benzodiazepine or Z-Drug] drugs are among the most widely used treatments in adult medicine. We estimate that approximately 6%–10% of US adults used these drugs in 2010, and the percentages may be higher in parts of Europe. By 1979, the Cancer Prevention Study I of the American Cancer Society had found that both cigarette smoking and hypnotic [Benzodiazepine or Z-Drug] consumption were associated with excessive deaths, but the hypnotic [Benzodiazepine or Z-Drug] findings were discounted since the Cancer Prevention Study I was not designed primarily to study these drugs.
At least 24 published studies have now examined mortality associated with hypnotic [Benzodiazepine or Z-Drug] consumption (supplemental table 1). Of the 24 cited, 18 reported significant (p<0.05) associations of hypnotic [Benzodiazepine or Z-Drug] usage with increased mortality.
Lack of uniformity of measured elements makes it impossible to incorporate the majority of these studies into a meta-analysis. Nevertheless, of 22 reports from which a risk or hazard ratio (HR) for hypnotic [Benzodiazepine or Z-Drug] associated deaths could be estimated, 21 observed a risk exceeding 1.0 (p<0.001).
One study observed a RR of 1.0 associating total mortality with hypnotics but found hypnotic [Benzodiazepine or Z-Drug] use significantly associated with cancer mortality. Three other studies have reported an association of hypnotics with cancer deaths.
These studies generally failed to report the specific hypnotic [Benzodiazepine or Z-Drug] drugs used by the participants, often confounded hypnotics with tranquilisers not marketed for treatment of insomnia, and usually omitted monitoring of the quantities of hypnotic [Benzodiazepine or Z-Drug] drugs provided participants during the follow-up intervals. Moreover, previous studies had insufficient data on the short-acting benzodiazepine agonists such as zolpidem, zaleplon, and eszopiclone that now dominate the US market because their shorter duration of action is believed to provide improved safety.
Using data from longitudinal electronic medical records maintained by a large integrated US health system, the authors planned a matched cohort study to contrast mortality and cancer associations of zolpidem and other new short-acting hypnotics [Benzodiazepines and Z-Drugs] with controls and with older hypnotics.
Results
Zolpidem was the most frequently prescribed hypnotic [Benzodiazepine or Z-Drug] drug during the study interval from 2002 to 2006, and temazepam was the next most common…
Associations between hypnotic [Benzodiazepine or Z-Drug] use and death
Patients prescribed any hypnotic [Benzodiazepine or Z-Drug] had substantially elevated hazards of dying compared to those with equivalent comorbidity who took no hypnotics. Importantly, the death hazard was evident even in the lowest tertile of use…
For any hypnotic [Benzodiazepine or Z-Drug], or for zolpidem or temazepam specifically, the hazards of death in the middle tertiles of use were four to five times higher in users compared to non-users, and the hazards in the highest tertiles were five- or sixfold greater than those in non-users, indicating dose–response relationships for zolpidem and temazepam specifically and for any hypnotic [Benzodiazepine or Z-Drug].
HRs associated with levels of hypnotic consumption from Cox proportional hazards survival analyses, controlled for age, gender, ethnicity, smoking status, body mass index, marital status and alcohol use and stratified by diagnoses in 12 classes of comorbidity. N: number of patients in each dose group for deaths. Restrictions of stratification produced small differences in N for the cancer analyses. p: probability that HR=1 from Cox proportional hazards models. For each drug, the top p level is for the overall contrast among dosage categories (including the no medication or reference category), and the lower p values are for the significance of each HR referenced to no hypnotic use. HR: hazard ratio for death or cancer (95% CI). Models for zolpidem and temazepam excluded patients receiving other hypnotics. See the supplemental files for additional HRs.
The death HR associated with prescriptions for less commonly prescribed hypnotic [Benzodiazepine or Z-Drug] drugs were likewise elevated, and the confidence limits of death hazards for each other hypnotic [Benzodiazepine or Z-Drug] overlapped that for zolpidem, with the exception of eszopiclone, which was associated with higher mortality (see supplemental files).
Associations between hypnotic [Benzodiazepine or Z-Drug] use and incident major cancer
Since prior studies suggested an association between hypnotics [Benzodiazepines and Z-Drugs] and deaths from major cancers, we constructed Cox models for major cancer incidence (ie, excluding non-melanoma skin cancer incidence) and excluding all patients who had major cancers diagnosed before the period of observation. As shown in table 3, there were modestly increased statistically significant cancer HRs for those prescribed any hypnotic [Benzodiazepine or Z-Drug] compared to non-users, with the middle and highest tertiles having cancer HRs of 1.20 (95% CI 1.03 to 1.40) and 1.35 (95% CI 1.18 to 1.55), respectively. The association with zolpidem was significant for the highest tertile. The HRs for temazepam were significant for the middle tertile and the highest tertile. The cancer HR of 1.99 (95% CI 1.75 to 2.52) for the highest tertile of temazepam was significantly greater than the corresponding HRs for zolpidem or for all hypnotics combined.
Discussion
Patients with prescriptions for hypnotics [Benzodiazepines or Z-Drugs] had approximately 4.6 times the hazard of dying over an average observation period of 2.5 years as compared to non-users. These findings were robust with adjustment for multiple potential confounders and consistent using multiple strategies to address confounding by health status. A dose–response effect was seen. Among users in the highest tertiles of annualised dosages, the HRs for death were 5.3, 5.7 and 6.6, respectively, for all hypnotics [Benzodiazepines and Z-Drugs], zolpidem alone and temazepam alone. This top third of users were prescribed 92.8% of all the prescription doses of hypnotics [Benzodiazepines and Z-Drugs] (supplemental figure 2). Those in the top third were also 35% more likely to develop a new major cancer.
Perhaps the most striking finding was that an increased hazard for death was present even in the lowest tertile of hypnotic [Benzodiazepine or Z-Drug] use, such that hypnotic [Benzodiazepine or Z-Drug] drugs were associated with a 3.6-fold increased risk of dying for patients using <18 hypnotic [Benzodiazepine or Z-Drug] pills per year…
Multiple causal pathways by which hypnotics might lead to mortality have been demonstrated…
Conclusions
Rough order-of-magnitude estimates at the end of the supplemental files suggest that in 2010, hypnotics may have been associated with 320 000 to 507 000 excess deaths in the USA alone…
…the consistency of our estimates across a spectrum of health and disease suggests that the mortality effect of hypnotics [Benzodiazepines and Z-Drugs] was substantial.
Excess mortality is associated with hypnotic [Benzodiazepine or Z-Drug] use.